This article explores how Sumitomo Pharma America (SMPA) leveraged H1’s advanced data capabilities to integrate diverse insights, enhance field medical strategies, and foster cross-functional collaboration across therapeutic areas.
We’ve developed real-time software that MA HQ and MSLs are already using daily to improve their physician insights, tailor field deployment and education, and track impact at the national, local, and individual physician level.
Take advantage of alternative impact metrics that better reflect the multidimensional nature of today’s research dissemination and consumption.
Dig into best practices for measuring the operational effectiveness of Medical Affairs teams, emphasizing the importance of establishing a strong foundation of data and metrics to demonstrate impact and value within pharmaceutical organizations.
Medical Affairs is in the unique position to drive health equity through three main roles: catalyser, capabilities enhancer, and cross-functional collaborator, emphasizing the need for deliberate strategies and actions to close health gaps and improve outcomes for underserved populations.
Digital Science held a roundtable discussion with Medical Affairs leaders in Madrid in May 2024 on the topic of scientific communications strategies assessment and their success measurements for multiple stakeholders.
The MAPS Puerto Rico Roundtable hosted by Real Chemistry in March 2024 discussed the integration of digital platforms, AI, and personalized content to enhance engagement with healthcare providers (HCPs). The panel emphasized the shift towards real-time, tailored information delivery and the importance of leveraging insights from both traditional and digital sources to support effective engagement strategies while ensuring compliance.
Drawing on insights from a roundtable of industry leaders convened by Klick at the recent MAPS conference, let’s look at how viewing the KOL holistically can lead to new avenues of engagement and more multifaceted relationships.
Addressing the critical importance of integrating robust scientific understanding into the commercial journey, pinpointing the need for medical affairs to take the helm in defining and communicating the commercial value of healthcare innovations.
From the choice of where to publish to the assessment of impact, every decision holds weight in medical research publication. And yet, the metrics that have been traditionally used to guide these decisions offer only a partial view. The result: a hit-or-miss situation when it comes to reaching the target audience—healthcare professionals (HCPs) and patients. Can a data-driven approach that incorporates both traditional and the newer alternative metrics hold the key to improved publication planning, impact and thereby better patient outcomes?